Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrinabdione - VivaCell Biotechnology Espana

Next Previous
Search
Drug Profile

Etrinabdione - VivaCell Biotechnology Espana

Alternative Names: EHP-101; VCE-004; VCE-004.8

Latest Information Update: 20 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VivaCell Biotechnology Espana
  • Developer Emerald Health Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Cannabinoids; Neuroprotectants; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists; Protein phosphatase 2A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral arterial disorders
  • Discontinued Diffuse scleroderma; Multiple sclerosis

Most Recent Events

  • 14 Jan 2025 VivaCell Biotechnology Espana plans phase-IIa CLAUDIA trial for Peripheral arterial disorders in Spain (NCT06774040),
  • 11 Dec 2023 Phase-II clinical trials in Peripheral arterial disorders (PO), before December 2023 (VivaCell Biotechnology Espana pipeline, December 2023)
  • 21 Sep 2023 Emerald Health Pharmaceuticals terminates a Phase-II clinical trials in Diffuse scleroderma in Australia, New Zealand, USA and Puerto Rico as of September 2023 due to company ceasing all its operations due to shut down (PO) (NCT04166552)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top